B. TABLE 1.—ADDRESSES FOR CURRICULUM VITAE AND NOMINATIONS—Continued

Advisory Committee	Type of Representative	Contact Person	Office/Center/ Mail Code	Addresses/ E-mail	Telephone
DGMPAC	Industry and government representatives	Sharon Kalokerinos	CDRH (HFZ–300)	2094 Gaither Rd., Rockville, MD 20850, or smk@cdrh.fda.gov	301–594–4613 ext. 139
TEPRSSC	Industry and government representatives	Orhan Suleiman	CDRH (HFZ–240)	1350 Piccard Dr., Rockville, MD 20850, or ohs@cdrh.fda.gov	301–594–3533
NMQAAC, DGMPAC, TEPRSSC	Consumer and general public representatives	Linda A. Sherman	Office of the Senior Associate Commissioner for Office of External Relations (HF–4)	5600 Fishers Lane, Rockville, MD 20857, or lsherman@oc.fda.gov	301–827–1220

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.

Dated: June 10, 2002.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 02–15210 Filed 6–17–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Protection of Human Subjects in Clinical Trials; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: Protection of Human Subjects in Clinical Trials. The topics to be discussed are the role of FDA, institutional review boards, and other stakeholders in the protection of human subjects in clinical trials as it relates to minority participation.

Date and Time: The meeting will be held on August 22, 2002, from 7:30 p.m. to 9 p.m.

Location: The meeting will be held at Meharry Medical School, West Basic Science Building Auditorium, rm. M001, 21st Avenue North at Meharry Blvd., Nashville, TN 37208.

Contact: Sandra S. Baxter, Southeast Region, New Orleans District Office, Food and Drug Administration, 297 Plus Park Blvd., Nashville, TN 37217, 615–781–5385, ext. 122, FAX 615–781–5383, e-mail: sbaxter@ora.fda.gov.

Registration and Requests for Oral Presentations: Send registration information (including name, title, firm name, address, telephone, and fax number), and written material and requests to make oral presentations, to the contact person by August 8, 2002.

If you need special accommodations due to a disability, please contact Sandra S. Baxter at least 7 days in advance.

Transcripts: Transcripts of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page.

Dated: June 10, 2002.

John Marzilli,

Acting Senior Associate Commissioner for Regulatory Affairs.

[FR Doc. 02–15279 Filed 6–17–02; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99D–5199]

Medical Devices; Guidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and/or Pelvic Surgery; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the guidance entitled ''Guidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and/or Pelvic Surgery.'' This guidance is intended to provide guidance on the preclinical testing recommended for resorbable adhesion barrier devices used in abdominal and/or pelvic surgery. This guidance is being issued to finalize the previous draft version issued on December 16, 1999.

DATES: Submit written or electronic comments concerning this guidance at any time.

ADDRESSES: Submit written requests for single copies on a 3.5″ diskette of the guidance document entitled ''Guidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and/or Pelvic Surgery'' to the Division of Small Manufacturers, International, and Consumer Assistance (HFZ–220), Center for Devices and Radiological Health (CDRH), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. Send two self-addressed adhesive labels to assist that office in processing your request, or fax your request to 301–443–8818. Submit written comments concerning this guidance to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify comments with the docket number found in brackets in the heading of this document. Submit electronic comments to *http://www.fda.gov/dockets/ecomments*. *See* the **SUPPLEMENTARY INFORMATION** section for information on electronic access to the guidance.

FOR FURTHER INFORMATION CONTACT: Joyce M. Whang, Center for Devices and Radiological Health (HFZ–470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–1180

SUPPLEMENTARY INFORMATION:

I. Background

This guidance document is intended to provide guidance on the preclinical and clinical testing recommended for resorbable adhesion barrier devices used in abdominal and/or pelvic surgery. It was developed jointly by the Division of General, Restorative and Neurological Devices, and the Division of Reproductive, Abdominal and Radiological Devices. The final version of this guidance supersedes the draft